GlassScriptPhysician profile
Roman M Ostrowski
NPI 1154459030
$9,977.58
in general payments reported to CMS, 2019-2025
25 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $1,552 · 2021: $1,416 · 2022: $1,965 · 2023: $1,422 · 2024: $1,472 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,869 · Education: $57.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,868.77 |
| Education | $57.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,207.65 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,505.23 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,073.91 | 2019-2024 | Ofev |
| Genzyme Corporation | $1,069.61 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $740.25 | 2020-2025 | Dupixent |
| Gilead Sciences, INC. | $561.16 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $380.20 | 2019-2022 | |
| Amgen INC. | $265.30 | 2022-2024 | Tezspire, Otezla, Repatha |
| Abbvie INC. | $152.90 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $123.35 | 2019-2021 | |
| Pfizer INC. | $122.08 | 2021 | |
| Lilly USA, LLC | $118.61 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Insmed, INC. | $111.78 | 2020 | |
| Mylan Specialty L.P. | $99.58 | 2021-2023 | Yupelri |
| Allergan, INC. | $95.73 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $79.86 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $47.75 | 2022 | |
| Philips North America LLC | $29.03 | 2023 | |
| Currax Pharmaceuticals LLC | $28.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.22 | 2019 | |
| Amarin Pharma, INC. | $19.44 | 2022 | |
| Electromed, INC. | $17.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.50 | 2024 | Camzyos |
| Almatica Pharma LLC | $13.50 | 2023 | Gralise, Sertraline Hcl, Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Ostrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.